热门资讯> 正文
强生支持的Rapport Therapeutics IPO定价为每股17美元
2024-06-07 13:44
- Rapport Therapeutics (RAPP), backed by the venture capital arm of Johnson & Johnson (JNJ), on Thursday announced the pricing of its initial public offering of 8M shares of its common stock at a public offering price of $17.00 per share.
- The gross proceeds to Rapport (RAPP) from the initial public offering and the concurrent private placement, are expected to be approximately $154 million.
- Rapport’s (RAPP) shares are expected to begin trading on the Nasdaq Global Market on June 7, under the ticker symbol “RAPP.”
- The offering is expected to close on June 10.
- Source: Press Release
More on Rapport Therapeutics, Inc.
- Rapport Therapeutics Seeks IPO For CNS Treatment Programs
- J&J-backed Rapport Therapeutics sets terms for $136M IPO
- J&J-backed Rapport Therapeutics files for $100M IPO
- Financial information for Rapport Therapeutics, Inc.
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
